ENDRA Life Sciences Inc. — Director's Dealing 2022

May 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2022-05-16

Reporting Person: Tokman Alexander Y (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-16	Common Stock	P	100000	$0.1963	Acquired	132857	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1911 to $0.1963, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.